Tiziana says intranasal drug shows potential to ease Long COVID “brain fog” [Yahoo! Finance]
Tiziana Life Sciences Ltd - Common Shares (TLSA)
Company Research
Source: Yahoo! Finance
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function linked to Long COVID, according to a study published on bioRxiv. The study evaluated foralumab, a fully human anti-CD3 monoclonal antibody administered through the nose, in a mouse model designed to mimic neurological symptoms of Long COVID without direct viral infection of the brain. Researchers found the treatment reduced neuroinflammation, increased regulatory T cells in the brain and restored the formation of new neurons in the hippocampus, a region associated with memory. The therapy also improved short-term memory in the animals, the company said. The research included observational data showing that patients with neurological symptoms of Long COVID had lower levels of circulating regulatory T cells. Tiziana said the findings support the potential of intranasal anti-CD3 ther
Show less
Read more
Impact Snapshot
Event Time:
TLSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSA alerts
High impacting Tiziana Life Sciences Ltd - Common Shares news events
Weekly update
A roundup of the hottest topics
TLSA
News
- Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionGlobeNewswire
- Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressGlobeNewswire
- Tiziana Reports Promising Data Showing Nasal Anti-CD3 May Improve Age-Related Cognitive Decline [TheStreet.com]TheStreet.com
- Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingGlobeNewswire
- Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAGlobeNewswire
TLSA
Sec Filings
- 4/16/26 - Form 6-K
- 4/14/26 - Form 6-K
- 4/1/26 - Form 6-K
- TLSA's page on the SEC website